PMC:7796052 / 3448-3637 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"134","span":{"begin":167,"end":169},"obj":"Gene"},{"id":"135","span":{"begin":38,"end":40},"obj":"Gene"},{"id":"137","span":{"begin":103,"end":124},"obj":"Disease"}],"attributes":[{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"Gene:3827"},{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"Gene:3827"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:D054179"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"[18].\nNowadays, icatibant is the only BK antagonist approved as therapeutic agent for the treatment of hereditary angioedema [19], in spite of the number of selective BK ligands described i"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":114,"end":124},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0100665"}],"text":"[18].\nNowadays, icatibant is the only BK antagonist approved as therapeutic agent for the treatment of hereditary angioedema [19], in spite of the number of selective BK ligands described i"}